Research
Hormonal
GLP-1a therapy was associated with a mean change in HbA1c of −1.00% (±2.07) in treated patients compared to −0.83% (±1.92) in those without GLP-1a therapy.
GLP-1a therapy may lead to modest reductions in HbA1c in a real-world setting.
StrongQualifiesmedium confidence
Treated patients had a mean change in HbA1c of −1.00% (±2.07) compared to −0.83% (±1.92) in the without GLP-1a group (p = 0.27).
Why this rating
Based on study design from abstract.
Source
Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population
E. Paleček et al. · Journal of Investigative Medicine · 2024
DOI 10.1177/10815589241270427
cohort · n=693Cited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1a therapy was associated with a mean change in body mass index (BMI) of −0.83 kg/m2 in treated patients compared to −0.70 kg/m2 in those without GLP-1a therapy.Strong
- In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →